Dupixent® (dupilumab) late-breaking phase 3 copd results presented at ats and simultaneously published in the new england journal of medicine

Dupixent is the first and only investigational biologic for copd that has demonstrated a significant reduction in moderate or severe acute exacerbations by 30% compared to placebo

REGN Ratings Summary

REGN Quant Ranking